Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > History Of changes..,
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(196)
•••
Post by scarlet1967on Sep 24, 2022 12:02pm
226 Views
Post# 34984134

History Of changes..,

History Of changes..,

History of Changes for Study: NCT05383456

History of Changes for Study: NCT05383456

 

History of Changes for Study: NCT05388474

 

 

I know everyone is awaiting the results from phase1b including myself but again they have two commercial products generating revenues and the NASH “asset”.

The purpose of the ongoing multiple studies for both drugs is to evaluate/conclude additional safety/efficacy of the legacy drugs for their current approved(Trogarzo) and additional therapeutic benefits(Tesamorelin). As an investor I personally would like to know the prospects of all THTX’s operations  commercial and 

R&D as each and everyone can add value!

Also they got another patent(modified version covering more claims) approved in Japan latest publication in July and now active!

 

“Peptide compounds and peptide conjugates for the treatment of cancer with receptor-mediated chemotherapy”

 

https://patents.google.com/patent/WO2017088058A1/en

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities